{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:52:58Z","timestamp":1776430378979,"version":"3.51.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,17]],"date-time":"2027-04-17T00:00:00Z","timestamp":1807920000000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000963","name":"American Diabetes Association Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacl.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:26:59Z","timestamp":1769214419000},"page":"817-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxychloroquine alters lipoprotein particle concentrations and composition"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-3303","authenticated-orcid":false,"given":"Thiago B.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-8477","authenticated-orcid":false,"given":"Rachel G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico G.S.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2026.01.012_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jacl.2026.01.012_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2022.04.058","article-title":"Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K\/Akt signaling pathway","volume":"610","author":"Li","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacl.2026.01.012_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.972397","article-title":"Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes","volume":"13","author":"Jin","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2026.01.012_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","article-title":"Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition","volume":"195","author":"Torigoe","year":"2018","journal-title":"Clin Immunol"},{"issue":"15","key":"10.1016\/j.jacl.2026.01.012_bib5","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/14656566.2024.2412252","article-title":"Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus","volume":"25","author":"Paredes-Ruiz","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacl.2026.01.012_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2021.04.062","article-title":"Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: the randomized, double-blind, placebo-controlled OXI pilot trial","volume":"337","author":"Ulander","year":"2021","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1007\/s10067-022-06282-0","article-title":"Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease","volume":"41","author":"Wakiya","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.012_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/dom.14333","article-title":"The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant\u00a0adults: a randomized trial","volume":"23","author":"Toledo","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jacl.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","article-title":"Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial","volume":"58","author":"Wasko","year":"2015","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF02535017","article-title":"Inhibition of hepatic cholesterol biosynthesis by chloroquine","volume":"16","author":"Beynen","year":"1981","journal-title":"Lipids"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0002-9343(94)90151-1","article-title":"Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis","volume":"96","author":"Petri","year":"1994","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.012_bib12","first-page":"575","article-title":"Early determinants of atherosclerosis in paediatric systemic lupus erythematosus","volume":"29","author":"Boros","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.012_bib13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/acr.22341","article-title":"Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications","volume":"66","author":"Kerr","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.012_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RHU.0000000000000502","article-title":"Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients","volume":"23","author":"Restrepo","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib16","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00431-023-04837-0","article-title":"Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial","volume":"182","author":"Gheet","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.012_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00124743-199702000-00002","article-title":"Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus","volume":"3","author":"Kavanaugh","year":"1997","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.012_bib18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/acr.22285","article-title":"Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","article-title":"Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone","volume":"30","author":"Pareek","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.012_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"77","author":"Rempenault","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaad.2020.12.013","article-title":"Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: a Danish nationwide cohort study","volume":"84","author":"Haugaard","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/acr.24850","article-title":"Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.012_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.32190","article-title":"Hydroxychloroquine and cardiovascular events in patients with systemic lupus erythematosus","volume":"7","author":"Grimaldi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.012_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"issue":"10","key":"10.1016\/j.jacl.2026.01.012_bib28","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.012_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCOUTCOMES.113.000675","article-title":"High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease","volume":"7","author":"Akinkuolie","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"14","key":"10.1016\/j.jacl.2026.01.012_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034763","article-title":"High-density lipoprotein particle concentration and size predict incident coronary artery disease events in a cohort with type 1 diabetes","volume":"13","author":"Costacou","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002600","article-title":"Large HDL subfraction but not HDL-C is closely linked with risk factors, coronary severity and outcomes in a cohort of nontreated patients with stable coronary artery disease: a prospective observational study","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.012_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrendo.2011.235","article-title":"The emerging role of HDL in glucose metabolism","volume":"8","author":"Drew","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jdi.14172","article-title":"High-density lipoprotein in diabetes: structural and functional relevance","volume":"15","author":"Lui","year":"2024","journal-title":"J Diabetes Investig"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.012_bib34","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2337\/dc15-0625","article-title":"Differential association between HDL subclasses and the development of type 2 diabetes in a prospective study of Japanese Americans","volume":"38","author":"Hwang","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1210\/clinem\/dgab075","article-title":"HDL particle subspecies and their association with incident type 2 diabetes: the PREVEND study","volume":"106","author":"Sokooti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","article-title":"Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis","volume":"298","author":"Wasko","year":"2007","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.jacl.2026.01.012_bib37","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/rheumatology\/keu451","article-title":"Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study","volume":"54","author":"Chen","year":"2015","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.012_bib39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","article-title":"Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis","volume":"76","author":"Ozen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.012_bib40","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.012_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"10.1016\/j.jacl.2026.01.012_bib42","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1016\/S0021-9258(17)39707-7","article-title":"Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells","volume":"259","author":"Chen","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2026.01.012_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.athplu.2024.02.002","article-title":"OXI pilot trial. The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical study","volume":"55","author":"Simonen","year":"2024","journal-title":"Atheroscler Plus"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.012_bib44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/09612033221090127","article-title":"Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: a possible mechanism for the reversal of atherosclerosis in the disease","volume":"31","author":"Lang","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jacl.2026.01.012_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2021.03.028","article-title":"Safety of treatment with chloroquine and hydroxychloroquine: a ten-year systematic review and meta-analysis","volume":"88","author":"Edington","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.012_bib46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/10600280231204969","article-title":"Hydroxychloroquine-chloroquine, QT-prolongation, and major adverse cardiac events: a meta-analysis and scoping review","volume":"58","author":"Garcia","year":"2024","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:01:53Z","timestamp":1776427313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1933287426000139"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.01.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine alters lipoprotein particle concentrations and composition","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}